Opinion

Video

Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Caroline Vovan
1 expert is featured in this series.
1 expert is featured in this series.
Dr María Díez Campelo
Dr Caroline Vovan
Guy Young, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo